Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for bladder cancer.

A M Kamat1, D L Lamm

  • 1Department of Urology, PO Box 9251, Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.

Current Urology Reports
|June 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.

ESMO open·2025
Same author

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.

ESMO open·2025
Same author

Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.

ESMO open·2024
Same author

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.

Urologic oncology·2022
Same author

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis.

Cell death discovery·2016
Same journal

Single Port Robotic Surgery in Benign Urologic Disease - A Review of Contemporary Applications and Outcomes.

Current urology reports·2026
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
See all related articles

Bacille Calmette-Guérin (BCG) immunotherapy is the most effective treatment for superficial bladder cancer, reducing recurrence and improving survival. Optimal use of BCG therapy requires careful attention to administration details.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Superficial bladder cancers, including carcinoma in situ, Ta, and T1 stages, are primarily treated with immunotherapy.
  • Various immunotherapeutic agents like bacille Calmette-Guérin (BCG), interferon, and gene therapy aim to treat tumors, prevent recurrence, and prolong patient survival.

Purpose of the Study:

  • To review recent advances in immunotherapy for bladder cancer.
  • To emphasize the efficacy and optimal application of bacille Calmette-Guérin (BCG) therapy for transitional cell carcinoma.

Main Methods:

  • Literature review of recent advances in bladder cancer immunotherapy.
  • Focus on bacille Calmette-Guérin (BCG) therapy for transitional cell carcinoma.

Main Results:

Related Experiment Videos

  • Bacille Calmette-Guérin (BCG) is currently the most effective immunotherapeutic agent for superficial transitional cell carcinoma.
  • BCG therapy demonstrates a positive impact on reducing tumor recurrence, preventing disease progression, and enhancing patient survival.

Conclusions:

  • Immunotherapy, particularly BCG, plays a crucial role in managing superficial bladder cancer.
  • Maximizing the benefits of BCG immunotherapy necessitates meticulous attention to maintenance schedules, administration, dosage, strains, and viability.